Laekna, Inc. (HK:2105) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Laekna, Inc. has successfully dosed all subjects in its Phase I clinical trial of LAE102, aimed at treating obesity. Early results show promising safety and biomarker changes, signaling progress in their innovative weight control therapy. The company plans to proceed with further trials while maintaining strong financial discipline to support its clinical advancements.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.